Early money Earlier this week California introduced a bill to decriminalize psychedelics. If passed, SB 519 will approve the use of mushrooms, MDMA, LSD, mescaline, and ibogaine for…
Psychedelics
COMPASS Pathways (CMPS.Q) reported further results from a Phase I study on their COMP360 psilocybin conducted at King’s College London. The study was a randomized, double-blind, placebo-controlled study intended…
Mindset Pharma (MSET.C) announced their lead clinical candidate, MSP-1014. MSP-1014 is a differentiated psilocybin-based compound from Mindset’s Family 1 of novel, patent-pending psychedelic compounds. MSET plans on moving forward…
On May 27, Delic Holdings (DELC.C) announced they have acquired all of the issued and outstanding shares in the capital of Complex Biotech Discovery Ventures (CBDV), completing their acquisition…
Cybin (CYBN.NE) announced they are sponsoring Kernel’s feasibility study of its Kernel Flow technology to measure Ketamine’s psychedelic effect on cerebral cortex hemodynamics. Cybin announced in January that they…
A different approach to MDD I’m big on companies having a unique approach to whatever they are doing. Many psychedelics companies are targetting depression but from a psychedelic-assisted therapy…
Mind Medicine (MMED.NE) announced the publication of the first pharmacogenetic data on LSD to help personalize dosing. The study results from a pooled secondary analysis of four Phase I…
Cybin (CYBN.NE) announced they have filed an international patent application that brings the potential to obtain patent coverage in 153 countries. The application is governed by the Patent Cooperation…
‘Growth hacking’ Early on in the shroom boom critics had one major pain point – legalization is too far away. I remember the stiffs at the Cannacord conference a…
Mydecine Innovations Group (MYCO.C) announced that they have received approval from Health Canada to significantly expand their cultivation capacity at their Canadian Current Good Manufacturing Practice (cGMP) facility at…